Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sylke Roth-Eichhorn"'
Autor:
Laura R. Kuck, Sylke Roth-Eichhorn, Sam Loob, Kathy L. Rowlen, Stephen Saye, Rose T. Byrne-Nash
Publikováno v:
Vaccine. 35:1918-1925
Vaccine manufacturers require more rapid and accurate tools to characterize the potency and stability of their products. Currently, the gold standard for influenza vaccine potency is the single radial immunodiffusion (SRD) assay, which has inherent d
Autor:
Katrin Plötze, Stephan Schüler, Michael Kasper, Richard Funk, Ina Schade, Hildegard Kuss, Sylke Roth-Eichhorn
Publikováno v:
Transplantation. 74:326-334
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors recommend these drugs for immunosuppressive therapy after lung transplantation. The potency of three PDE4 inhibitors was tested u
Publikováno v:
Graft. 5:156-160
Publikováno v:
Journal of Hepatology. 30:612-620
Background/Aims: The transformation of hepatic stellate cells into myofibroblasts is a key step in the pathogenesis of fibrotic liver diseases. The intracellular signaling associated with hepatic stellate cell transformation becomes a point of intere
Publikováno v:
Hepatology. 28:1588-1596
Recently, the existence of the large latent transforming growth factor β (TGF-β) complex, consisting of TGF-β, the N-terminal part of its precursor (latency-associated peptide [LAP]), and the latent TGF-β binding protein (LTBP), was demonstrated
Autor:
Richard Funk, Michael Kasper, Ina Schade, Jaqueline Wunderlich, Katrin Ploetze, Stephan Schueler, Sylke Roth-Eichhorn
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 20(11)
Background Potent prevention and therapy of obliterative bronchiolitis may enhance long-term survival after lung transplantation. Phosphodiesterase-4 inhibitors have been established for anti-inflammatory treatment, particularly of pulmonary diseases